Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A.

J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24.

PMID:
31233639
2.

Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.

Hadaya D, Gkouveris I, Soundia A, Bezouglaia O, Boyce RW, Stolina M, Dwyer D, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S.

J Bone Miner Res. 2019 Jan;34(1):171-181. doi: 10.1002/jbmr.3581. Epub 2018 Sep 24.

PMID:
30184271
3.

Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.

Taylor S, Hu R, Pacheco E, Locher K, Pyrah I, Ominsky MS, Boyce RW.

Bone Rep. 2018 Mar 15;8:95-103. doi: 10.1016/j.bonr.2018.03.002. eCollection 2018 Jun.

4.

Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody.

Boyce RW, Brown D, Felx M, Mellal N, Locher K, Pyrah I, Ominsky MS, Taylor S.

Bone Rep. 2018 Mar 3;8:90-94. doi: 10.1016/j.bonr.2018.03.001. eCollection 2018 Jun.

5.

The Automatic Proportionator Estimator Is Highly Efficient for Estimation of Total Number of Sparse Cell Populations.

Boyce RW, Gundersen HJG.

Front Neuroanat. 2018 Mar 21;12:19. doi: 10.3389/fnana.2018.00019. eCollection 2018.

6.
7.

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.

Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW.

J Bone Miner Res. 2017 Apr;32(4):788-801. doi: 10.1002/jbmr.3036. Epub 2016 Dec 13.

8.

Effects of sclerostin antibodies in animal models of osteoporosis.

Ominsky MS, Boyce RW, Li X, Ke HZ.

Bone. 2017 Mar;96:63-75. doi: 10.1016/j.bone.2016.10.019. Epub 2016 Oct 24. Review.

PMID:
27789417
9.

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.

Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, Ominsky MS, Pyrah I, Boyce RW.

Regul Toxicol Pharmacol. 2016 Nov;81:212-222. doi: 10.1016/j.yrtph.2016.08.010. Epub 2016 Aug 26. Review.

10.

Nonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth).

Fossey S, Vahle J, Long P, Schelling S, Ernst H, Boyce RW, Jolette J, Bolon B, Bendele A, Rinke M, Healy L, High W, Roth DR, Boyle M, Leininger J.

J Toxicol Pathol. 2016;29(3 Suppl):49S-103S. doi: 10.1293/tox.29.3S-2. Epub 2016 Jul 29. Review.

11.

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.

Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, Aguirre JI, Wronski TJ, Buntich S, Afshari CA, Pyrah I, Nioi P, Boyce RW.

Bone. 2016 Mar;84:148-159. doi: 10.1016/j.bone.2015.12.013. Epub 2015 Dec 22.

12.

A comparison of the Indian Health Service counseling technique with traditional, lecture-style counseling.

Lam N, Muravez SN, Boyce RW.

J Am Pharm Assoc (2003). 2015 Sep-Oct;55(5):503-10. doi: 10.1331/JAPhA.2015.14093.

PMID:
26359960
13.

Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.

Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW.

Bone. 2015 Dec;81:380-391. doi: 10.1016/j.bone.2015.08.007. Epub 2015 Aug 8.

14.

Journal of Bone and Mineral Research: Volume 30, Issue 5, May 2015, Frontmatter page ii.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW.

J Bone Miner Res. 2015 Jul;30(7):1347. doi: 10.1002/jbmr.2543. Epub 2015 May 10. No abstract available.

15.

OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

de Molon RS, Shimamoto H, Bezouglaia O, Pirih FQ, Dry SM, Kostenuik P, Boyce RW, Dwyer D, Aghaloo TL, Tetradis S.

J Bone Miner Res. 2015 Sep;30(9):1627-40. doi: 10.1002/jbmr.2490. Epub 2015 May 27.

16.

Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.

Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW.

J Bone Miner Res. 2015 Jul;30(7):1280-9. doi: 10.1002/jbmr.2480. Erratum in: J Bone Miner Res. 2015 Jul;30(7):1347.

17.

Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.

Nioi P, Taylor S, Hu R, Pacheco E, He YD, Hamadeh H, Paszty C, Pyrah I, Ominsky MS, Boyce RW.

J Bone Miner Res. 2015 Aug;30(8):1457-67. doi: 10.1002/jbmr.2482. Epub 2015 May 22.

18.

Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.

Boyce RW, Varela A, Chouinard L, Bussiere JL, Chellman GJ, Ominsky MS, Pyrah IT.

Bone. 2014 Jul;64:314-25. doi: 10.1016/j.bone.2014.04.002. Epub 2014 Apr 13.

PMID:
24727159
19.

Responses to "Is it time to start teaching basic diagnostics?".

Herrier RN, Apgar DA, Boyce RW.

Am J Pharm Educ. 2014 Mar 12;78(2):42. doi: 10.5688/ajpe78242. No abstract available.

20.

Cytokines associated with increased erythropoiesis in Sprague-Dawley rats administered a novel hyperglycosylated analog of recombinant human erythropoietin.

Andrews DA, Hamadeh HK, He YD, Boren BM, Turk JR, Boyce RW, Mytych DT, Barger TE, Salimi-Moosavi H, Sloey B, Elliott S, McElroy P, Sinclair AM, Shimamoto G, Pyrah IT, Lightfoot-Dunn RM.

Toxicol Pathol. 2014;42(3):540-54. doi: 10.1177/0192623313486318. Epub 2013 May 14.

PMID:
23674392
21.

Dose-related differences in the pharmacodynamic and toxicologic response to a novel hyperglycosylated analog of recombinant human erythropoietin in Sprague-Dawley rats with similarly high hematocrit.

Andrews DA, Boren BM, Turk JR, Boyce RW, He YD, Hamadeh HK, Mytych DT, Barger TE, Salimi-Moosavi H, Sloey B, Elliott S, McElroy P, Sinclair AM, Shimamoto G, Pyrah IT, Lightfoot-Dunn RM.

Toxicol Pathol. 2014;42(3):524-39. doi: 10.1177/0192623313486319. Epub 2013 May 14.

PMID:
23674391
22.

Society of toxicologic pathology position paper: review series: assessment of circulating hormones in nonclinical toxicity studies: general concepts and considerations.

Stanislaus D, Andersson H, Chapin R, Creasy D, Ferguson D, Gilbert M, Rosol TJ, Boyce RW, Wood CE.

Toxicol Pathol. 2012 Aug;40(6):943-50. doi: 10.1177/0192623312444622. Epub 2012 May 8. Review.

PMID:
22569585
23.

Recommendations for the evaluation of pathology data in nonclinical safety biomarker qualification studies.

Burkhardt JE, Pandher K, Solter PF, Troth SP, Boyce RW, Zabka TS, Ennulat D.

Toxicol Pathol. 2011 Dec;39(7):1129-37. doi: 10.1177/0192623311422082.

PMID:
22116771
24.

Modern pathology methods for neural investigations.

Hale SL, Andrews-Jones L, Jordan WH, Jortner BS, Boyce RW, Boyce JT, Switzer RC III, Butt MT, Garman RH, Jensen K, Krinke G, Little PB.

Toxicol Pathol. 2011 Jan;39(1):52-7. doi: 10.1177/0192623310394213. Epub 2011 Jan 6.

PMID:
21212254
25.

Design-based stereology: introduction to basic concepts and practical approaches for estimation of cell number.

Boyce RW, Dorph-Petersen KA, Lyck L, Gundersen HJ.

Toxicol Pathol. 2010 Dec;38(7):1011-25. doi: 10.1177/0192623310385140. Epub 2010 Oct 28. Review.

PMID:
21030683
26.

Choice of morphometric methods and consequences in the regulatory environment.

Boyce JT, Boyce RW, Gundersen HJ.

Toxicol Pathol. 2010 Dec;38(7):1128-33. doi: 10.1177/0192623310385141. Epub 2010 Sep 30.

PMID:
20884817
27.

Topic of histopathology blinding in nonclinical safety biomarker qualification studies.

Burkhardt JE, Ennulat D, Pandher K, Solter PF, Troth SP, Boyce RW, Zabka TS.

Toxicol Pathol. 2010 Jun;38(4):666-7. doi: 10.1177/0192623310371221. No abstract available.

PMID:
20530250
28.

Longitudinal changes in strength of police officers with gender comparisons.

Boyce RW, Jones GR, Schendt KE, Lloyd CL, Boone EL.

J Strength Cond Res. 2009 Nov;23(8):2411-8. doi: 10.1519/JSC.0b013e3181bac2ab.

PMID:
19826280
29.

Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry.

Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS.

J Histochem Cytochem. 2009 Sep;57(9):849-60. doi: 10.1369/jhc.2009.953497. Epub 2009 May 26.

30.

Effects of p38 MAP kinase inhibitors on the differentiation and maturation of erythroid progenitors.

Dalmas DA, Tierney LA, Zhang C, Narayanan PK, Boyce RW, Schwartz LW, Frazier KS, Scicchitano MS.

Toxicol Pathol. 2008 Dec;36(7):958-71. doi: 10.1177/0192623308327121.

PMID:
19126791
31.

Effects of food restriction on testis and accessory sex glands in maturing rats.

Rehm S, White TE, Zahalka EA, Stanislaus DJ, Boyce RW, Wier PJ.

Toxicol Pathol. 2008 Jul;36(5):687-94. doi: 10.1177/0192623308320275. Epub 2008 Jul 22.

PMID:
18648097
32.

Transcriptional profiling of laser capture microdissected rat arterial elements: fenoldopam-induced vascular toxicity as a model system.

Dalmas DA, Scicchitano MS, Chen Y, Kane J, Mirabile R, Schwartz LW, Thomas HC, Boyce RW.

Toxicol Pathol. 2008 Apr;36(3):496-519. doi: 10.1177/0192623307311400. Epub 2008 May 8.

PMID:
18467687
33.

Novel vascular lesions in mice given a non-peptide vitronectin receptor antagonist.

Rehm S, Thomas RA, Smith KS, Mirabile RC, Gales TL, Eustis SL, Boyce RW.

Toxicol Pathol. 2007 Dec;35(7):958-71.

PMID:
18098042
34.

Role of p38 in regulation of hematopoiesis: effect of p38 inhibition on cytokine production and transcription factor activity in human bone marrow stromal cells.

Scicchitano MS, McFarland DC, Tierney LA, Boyce RW, Frazier KS, Schwartz LW, Thomas HC.

Blood Cells Mol Dis. 2008 May-Jun;40(3):370-80. Epub 2008 Feb 21.

PMID:
18093851
35.

Physical activity, weight gain and occupational health among call centre employees.

Boyce RW, Boone EL, Cioci BW, Lee AH.

Occup Med (Lond). 2008 Jun;58(4):238-44. Epub 2007 Dec 13.

PMID:
18079143
36.

Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples.

Scicchitano MS, Dalmas DA, Bertiaux MA, Anderson SM, Turner LR, Thomas RA, Mirable R, Boyce RW.

J Histochem Cytochem. 2006 Nov;54(11):1229-37. Epub 2006 Jul 24.

PMID:
16864893
37.

Physical fitness, absenteeism and workers' compensation in smoking and non-smoking police officers.

Boyce RW, Perko MA, Jones GR, Hiatt AH, Boone EL.

Occup Med (Lond). 2006 Aug;56(5):353-6. Epub 2006 Jun 22.

PMID:
16793853
38.

Three dimensional reconstruction of a human breast carcinoma using routine laboratory equipment and immunohistochemistry.

Kurien T, Boyce RW, Paish EC, Ronan J, Maddison J, Rakha EA, Green AR, Ellis IO.

J Clin Pathol. 2005 Sep;58(9):968-72.

39.

Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO.

Mod Pathol. 2005 Oct;18(10):1295-304.

40.

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging.

Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, Willette RN.

J Pharmacol Exp Ther. 2003 Dec;307(3):939-46. Epub 2003 Oct 15.

PMID:
14561850
41.

Intervention assessment in an Indian health service pharmacy.

Reynolds ER, Boyce RW, Haxby DG, Goldberg BA, Stennett DJ.

J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):41-5.

PMID:
10665248
42.

An essential role for ectodomain shedding in mammalian development.

Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA.

Science. 1998 Nov 13;282(5392):1281-4.

43.

Communicating more effectively with physicians, Part 3.

Herrier RN, Boyce RW.

J Am Pharm Assoc (Wash). 1996 Oct;NS36(10):573-4. No abstract available.

PMID:
8908932
44.

Communicating more effectively with physicians, Part 2.

Herrier RN, Boyce RW.

J Am Pharm Assoc (Wash). 1996 Sep;NS36(9):547-8. No abstract available.

PMID:
8824072
45.
46.

Why won't physicians accept my advice?

Herrier RN, Boyce RW.

J Am Pharm Assoc (Wash). 1996 Apr;NS36(4):224, 284. No abstract available.

PMID:
8919597
47.

Myths about patient compliance.

Herrier RN, Boyce RW.

Am Pharm. 1995 Dec;NS35(12):12-3. No abstract available.

PMID:
8546069
48.

Histologic and immunocytochemical characterization of canine distemper-associated metaphyseal bone lesions in young dogs following experimental infection.

Baumgärtner W, Boyce RW, Weisbrode SE, Aldinger S, Axthelm MK, Krakowka S.

Vet Pathol. 1995 Nov;32(6):702-9.

PMID:
8592806
49.

Does counseling improve compliance?

Herrier RN, Boyce RW.

Am Pharm. 1995 Sep;NS35(9):11-2, 61. No abstract available.

PMID:
7484809
50.

Talking to patients about potential side effects.

Herrier RN, Boyce RW.

Am Pharm. 1995 Jul;NS35(7):11-2. No abstract available.

PMID:
7661099

Supplemental Content

Loading ...
Support Center